BACE1 and neurodegenerative disease: A novel 4-methylthiocoumarin derivative has been studied against acetylcholinesterase, butyrylcholinesterase, BACE1, β-amyloid aggregation, and oxidative stress involved in the pathogenesis of this neurodegenerative disease.